Zoetis Inc. $ZTS Position Reduced by Saratoga Research & Investment Management

Saratoga Research & Investment Management cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 93.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,400 shares of the company’s stock after selling 102,618 shares during the quarter. Saratoga Research & Investment Management’s holdings in Zoetis were worth $931,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ZTS. Global Wealth Strategies & Associates purchased a new stake in Zoetis during the fourth quarter valued at about $25,000. Lodestone Wealth Management LLC purchased a new stake in Zoetis during the fourth quarter valued at about $30,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis during the third quarter valued at about $31,000. Holos Integrated Wealth LLC purchased a new stake in Zoetis during the fourth quarter valued at about $32,000. Finally, Board of the Pension Protection Fund purchased a new stake in Zoetis during the fourth quarter valued at about $38,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on ZTS. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a research note on Friday. Citigroup started coverage on shares of Zoetis in a research note on Wednesday, April 15th. They set a “buy” rating and a $145.00 price objective for the company. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $137.50.

Zoetis Price Performance

NYSE ZTS opened at $74.11 on Friday. The firm has a market capitalization of $31.07 billion, a price-to-earnings ratio of 12.29, a price-to-earnings-growth ratio of 1.21 and a beta of 0.87. The company has a 50 day simple moving average of $112.28 and a 200-day simple moving average of $120.94. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $172.23.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts predict that Zoetis Inc. will post 6.91 earnings per share for the current fiscal year.

Insider Activity at Zoetis

In other Zoetis news, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael B. Mccallister acquired 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.